With liraglutide 3.0 mg and semaglutide there are GLP-1 receptor agonists, which are either already approved (liraglutide) or in clinical development (semaglutide), for weight management in obesity that demonstrated a cardiovascular benefit for patients with type 2 diabetes in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) and Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN6) trials (109, 110). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.